Literature DB >> 21436388

Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis.

Rémy Phan-Ba1, Amy Pace, Philippe Calay, Patrick Grodent, Frédéric Douchamps, Robert Hyde, Christophe Hotermans, Valérie Delvaux, Isabelle Hansen, Gustave Moonen, Shibeshih Belachew.   

Abstract

BACKGROUND: Ambulation impairment is a major component of physical disability in multiple sclerosis (MS) and a major target of rehabilitation programs. Outcome measures commonly used to evaluate walking capacities suffer from several limitations.
OBJECTIVES: To define and validate a new test that would overcome the limitations of current gait evaluations in MS and ultimately better correlate with the maximum walking distance (MWD).
METHODS: The authors developed the Timed 100-Meter Walk Test (T100MW), which was compared with the Timed 25-Foot Walk Test (T25FW). For the T100MW, the subject is invited to walk 100 m as fast as he/she can. In MS patients and healthy control volunteers, the authors measured the test-retest and interrater intraclass correlation coefficient. Spearman rank correlations were obtained between the T25FW, the T100MW, the Expanded Disability Status Scale (EDSS), and the MWD. The coefficient of variation, Bland-Altman plots, the coefficient of determination, and the area under the receiver operator characteristic curve were measured. The mean walking speed (MWS) was compared between the 2 tests.
RESULTS: A total of 141 MS patients and 104 healthy control volunteers were assessed. Minor differences favoring the T100MW over the T25FW were observed. Interestingly, the authors demonstrated a paradoxically higher MWS on a long (T100MW) rather than on a short distance walk test (T25FW).
CONCLUSION: The T25FW and T100MW displayed subtle differences of reproducibility, variability, and correlation with MWD favoring the T100MW. The maximum walking speed of MS patients may be poorly estimated by the T25FW since MS patients were shown to walk faster over a longer distance.

Entities:  

Mesh:

Year:  2011        PMID: 21436388     DOI: 10.1177/1545968310397204

Source DB:  PubMed          Journal:  Neurorehabil Neural Repair        ISSN: 1545-9683            Impact factor:   3.919


  20 in total

1.  The dual task-cost of standing balance affects quality of life in mildly disabled MS people.

Authors:  Letizia Castelli; Francesca De Luca; Maria Rita Marchetti; Giovanni Sellitto; Fulvia Fanelli; Luca Prosperini
Journal:  Neurol Sci       Date:  2016-01-04       Impact factor: 3.307

2.  Strength Training to Improve Gait in People with Multiple Sclerosis: A Critical Review of Exercise Parameters and Intervention Approaches.

Authors:  Mark M Mañago; Stephanie Glick; Jeffrey R Hebert; Susan Coote; Margaret Schenkman
Journal:  Int J MS Care       Date:  2019 Mar-Apr

3.  The subjective minimal important change for the Six Spot Step Test in people with multiple sclerosis - The Danish MS Hospitals Rehabilitation study.

Authors:  Uwe M Pommerich; John Brincks; Anders Guldhammer Skjerbæk; Ulrik Dalgas
Journal:  Acta Neurol Belg       Date:  2022-06-15       Impact factor: 2.471

4.  A Core Set of Outcome Measures for Adults With Neurologic Conditions Undergoing Rehabilitation: A CLINICAL PRACTICE GUIDELINE.

Authors:  Jennifer L Moore; Kirsten Potter; Kathleen Blankshain; Sandra L Kaplan; Linda C OʼDwyer; Jane E Sullivan
Journal:  J Neurol Phys Ther       Date:  2018-07       Impact factor: 3.649

5.  Cardiovascular responses in older adults with total knee arthroplasty at rest and with exercise on a positive pressure treadmill.

Authors:  Sandra C Webber; Karla J Horvey; Madison T Yurach Pikaluk; Scott J Butcher
Journal:  Eur J Appl Physiol       Date:  2013-12-22       Impact factor: 3.078

6.  Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions.

Authors:  Stefan Gingele; Moritz Koch; Anna Christina Saparilla; Gudrun M Körner; Jarle von Hörsten; Marina Gingele; Tabea Seeliger; Franz Felix Konen; Martin W Hümmert; Alexandra Neyazi; Martin Stangel; Thomas Skripuletz
Journal:  Ther Adv Neurol Disord       Date:  2021-04-16       Impact factor: 6.570

7.  Motor fatigue measurement by distance-induced slow down of walking speed in multiple sclerosis.

Authors:  Rémy Phan-Ba; Philippe Calay; Patrick Grodent; Gael Delrue; Emilie Lommers; Valérie Delvaux; Gustave Moonen; Shibeshih Belachew
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

8.  Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.

Authors:  N Voloshyna; E Havrdová; M Hutchinson; T Nehrych; X You; S Belachew; C Hotermans; D Paes
Journal:  Eur J Neurol       Date:  2014-12-15       Impact factor: 6.089

9.  The impact of slower walking speed on activities of daily living in patients with multiple sclerosis.

Authors:  M Yildiz
Journal:  Int J Clin Pract       Date:  2012-11       Impact factor: 2.503

10.  Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases.

Authors:  Michael Prugger; Thomas Berger
Journal:  Patient Relat Outcome Meas       Date:  2013-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.